Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efinaconazole - Kaken Pharmaceutical

Drug Profile

Efinaconazole - Kaken Pharmaceutical

Alternative Names: Clenafin; IDP-108; Jublia; KP-103

Latest Information Update: 14 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer AIM China; Almirall S.A.; Bausch Health Companies; Dong-A ST; Kaken Pharmaceutical; Main Life Corporation; Tai Tien Pharmaceuticals
  • Class Antifungals; Fluorobenzenes; Piperidines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 09 Nov 2023 Almirall expects regulatory submission outcome in Germany and Italy in the second half of 2024
  • 10 Nov 2022 Almirall announces intention to launch efinaconazole for Onychomycosis in 2023
  • 27 May 2022 Preregistration for Onychomycosis (In adults, In children, In adolescents) in Germany and Italy (Topical) - Decentralised procedure
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top